reaching point C over calendar time and relate these to the population that produced them we can calculate the incidence rate. This is the production rate of the disease by the population.
If now we apply a case-finding method capable of identifying presymptomatic disease to this same population we will identify all cases of disease that are at any point in their development before C back to point B -the minimum limit of the method in identifying disease. The number of cases found in this first application of the casefinding method, which are distributed over the whole segment between B and C, related to the population examined provide prevalence rates for presymptomatic disease identifiable by the particular method. (All reference to prevalence of disease hereafter will be understood to be related to presymptomatic disease.)
If we continue to apply the case-finding method to the population regularly at some appropriate interval all new disease will now be identified at or near point B and we can determine the incidence rate of the disease at point B. If we compared the incidence rate at point B with that previously determined at point C, using the unweighted average of the age specific rates to avoid the biasing effect of general mortality during the time interval B to C, we would expect to find them to be nearly the same. (Actually B will exceed C to the extent that there is a residuum of prevalent disease somewhere between B-C in development at the end of the life span.) This equality also assumes that other causes of mortality do not differentiate appreciably between persons with and without the presymptomatic disease.
The prevalent presymptomatic disease found between points B and C on first examination with the case-finding method is made up of a succession of disease cohorts that have passed point B and are moving towards point C. The incidence rate tells us the population's production rate for the disease per unit of calendar time, and the prevalence rate tells us how many cases of the disease are present-in the population at all times between points B and C in their development. It follows that the ratio of prevalence to incidence provides a measure of the interval B to C in the units of time used for expressing incidence (Dunn 1962 (Guiss 1955) . The data from the study provided age and sex specific prevalence rates of unsuspected lung cancer to compare with general population incidence rates. The ratio of the age specific prevalence rates identified in the survey to incidence rates determined in the Ten City Morbidity Survey of 1948-9 (Dorn & Cutler 1959) was 0-6 and 0-9 for men and women respectively, giving estimates for the B-C interval of Fig 1 of seven months and eleven months. The use of X-ray screening to bring lung cancers to earlier diagnosis appears not very promising from these estimates and subsequent experience with the survival of patients identified by this means have confirmed this discouraging prediction (Boucot et al. 1961 , British Medical Journal 1961 (Stevens & Weigen 1966) where age specific incidence rates for breast cancer predict their annual incidence would be 1-9 cases. The prevalence/incidence ratio from these data estimates the B-C interval of Fig 1 to plot survival for patients identified presymptomatically it will appear better than that for symptomatic disease because we have added some portion of the B-C time interval to each of our presymptomatic cases. We can estimate the average length of the B-C interval by our prevalence/incidence ratio described above, and use this as a handicapping point from which to plot survival of our presymptomatic cases. However, there is the added restriction that survival of cases of prevalent disease can never be compared to incident disease. This is a restriction difficult to accept since it will mean, in the mammography study previously referred to, the 8 breast cancer cases found on initial mammography must be discarded in favour of the 1 or 2 breast cancers that will be found per 1,000 women examined annually by periodic mammography. Only incident disease can be compared to incident disease. In our present discussion, incident disease found at point B of Fig 1 When the cytological examination is done on a population of women for the first time the prevalence of the preclinical disease in its various phases is determined. In Fig 4 the invasive cervical cancer greatly exceed that under the incidence rate curve for clinical cervical cancer. The length of the B-C interval of Fig 1, which can be determined by the ratio of the sum of the unweighted age specific prevalence rates of preclinical invasive cervical cancer and those for the incidence of clinical disease as shown in Fig 4, is 4 1 years. In other words it takes on the average about four years from the beginning of invasive cervical cancer to reach the point where symptoms will lead to diagnosis.
The second observation to be made from Fig 4 is t' c rapid rise in carcinoma-in-situ prevalence among young women, reaching a peak after age 30, which is maintained until after age 45. The prevalence rates then decrease precipitously to reach a much lower level between ages 50 and 60.
After age 60 there is again a slight rise which may or mlay not be real because of the selection bias that is particularly characteristic of these older women.
A thir-d important observation to be made from
Fig 4 is that at the time the prevalence rates of carcinoma-in-situ are falling after age 45, the prevalence rates of preclinical invasive cervical cancer are rapidly rising. This suggests that the menopause is the approximate time when unknown factors are providing optimum conditions for in-situ lesions to progress to stromal invasion.
In Fig 5 the age specific prevalence rates for carcinoma-in-situ found in British Columbia are shown for comparison with the Memphis rates.
The age intervals are ten years now instead of 5.
The similarity in shape of the curves is obvious, The first cytology examination identifies through suspicious and positive cytology the women that are somewhere between 0 and point C of Fig 1 in the pathogenesis of their disease. Subsequent re-examination at periodic intervals of those women initially found cytologically negative determines the incidence of newly developing cytological changes and in turn histopathology determines the lesions responsible for these changes. Expressing the examination intervals in person-years allows incidence rates to be determined for these early histopathological lesions.
Where the prevalence/incidence ratio is large, as it is for the various histopathological segments of cervical cancer development, and where the screening technique has an appreciable false negative error, the first rescreening will provide an inflated estimate of incidence. Incidence rates, therefore, should be determined from the second and subsequent rescreenings (Dunn 1953 ).
The bottom curve of Fig 6 shows the age specific incidence rates for carcinoma-in-situ of the cervix found in white women periodically examined after being found cytologically negative on their initial screening and first rescreening. The most important observation to make here is that carcinoma-in-situ reaches a peak incidence rate in the 25-29 year age group. This, it seems to me, is a surprising and significant finding. The fact that it follows the modal peak of age at marriage by some 7 or 8 years should have xtiological implications. Following this age period the incidence rate drops to a lower level which is maintained at least to age 55. Whether the incidence rate actually increases among older women is open to question because of few cases and the small numbers of person-years of observation. If we calculate the average duration of carcinoma-in-situ with the prevalence rates of Fig 4 and How can cytology be most effectively applied for cervical cancer case-finding in a population of women? Since the highest incidence occurs among women in their 20s, to incorporate cytology as a routine part of pre-and post-natal care provides a built-in opportunity to reach the great bulk of young women during their years of greatest risk. This might inculcate the habit of periodical examination. The increasing use of oral contraceptives brings women into the hands of physicians during the child-bearing years and offers another opportunity for screening women cytologically during their years of greatest risk. Until we are more certain of the effect of these hormone preparations on the cervical epithelium such examinations initially and periodically are essential. Women seen for menopausal symptoms also provide an opportunity for cytological examination and this age period seems the most likely time for an old in-situ lesion to become a new invasive cervical cancer. For older women the opportunities for screening and the expected results are less certain.
How big a proportion of newly developing disease has a short in-situ phase and how frequently cytology needs to be repeated to find these while they are still occult is a question for which we We still have questions to be answered in the application of this our most effective cancer case-finding method. I hope that workers in England, without many of the barriers and ihandicaps offered by our system of providing -medical care to this kind of study, will fill in some of the important details that are lacking in our knowledge of the pathogenesis of cervical cancer.
